1
|
Li H, Rose P, Rowicki P, Cutler C, McPhee JT, Frey C, Lemieux L, Pelette G, Ang JK, Liu R, Richardson DD. Advancing multiproduct resin reuse for development and clinical manufacturing of an antibody-based therapeutic. Biotechnol Prog 2024:e3434. [PMID: 38334252 DOI: 10.1002/btpr.3434] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/03/2023] [Revised: 10/11/2023] [Accepted: 01/11/2024] [Indexed: 02/10/2024]
Abstract
Chromatography resins used for purifying biopharmaceuticals are generally dedicated to a single product. For clinical manufacturing, this can result in resin being used only for a fraction of its potential lifetime. Extending the use of resins to multiple products can significantly reduce resin waste and cost. It can also improve manufacturing flexibility in case of raw material shortage during times such as the COVID-19 pandemic. The work presented herein describes an overarching multiproduct resin reuse (MRR) strategy, which includes a risk assessment, strategic planning, small-scale feasibility runs, and the successful execution of the MRR strategy to support Good manufacturing practice (GMP) clinical manufacturing of an antibody-based therapeutic. Specifically, an anion exchange (AEX) and cation exchange (CEX) MRR strategy is described. Clearance of carryover biological product is demonstrated by first cleaning the AEX and CEX manufacturing columns with sodium hydroxide to ensure inactivation and degradation of the carryover protein and followed by a blank buffer elution that is tested using various analytical methodologies to ensure reduction of the carryover protein to an acceptable level. To our knowledge, this is the first time an MRR approach has been successfully implemented and submitted to health authorities to support biologic GMP clinical manufacture.
Collapse
Affiliation(s)
- Hong Li
- Global CMC Project Management, Framingham, Massachusetts, USA
| | - Patricia Rose
- Process Research and Development, Merck & Co., Inc., Rahway, New Jersey, USA
| | - Patricia Rowicki
- Process Research and Development, Merck & Co., Inc., Rahway, New Jersey, USA
| | - Collette Cutler
- Process Research and Development, Merck & Co., Inc., Rahway, New Jersey, USA
| | - Jeffrey T McPhee
- Analytical Research and Development, Merck & Co., Inc., Rahway, New Jersey, USA
| | - Claudia Frey
- CMC Regulatory, Merck & Co., Inc., Rahway, New Jersey, USA
| | - Linda Lemieux
- CMC Regulatory, Merck & Co., Inc., Rahway, New Jersey, USA
| | - Gerald Pelette
- Global Development Quality, Merck & Co., Inc., Rahway, New Jersey, USA
| | - Joo Kok Ang
- Global Development Quality, Merck & Co., Inc., Rahway, New Jersey, USA
| | - Ren Liu
- Process Research and Development, Merck & Co., Inc., Rahway, New Jersey, USA
| | | |
Collapse
|
2
|
Stiving AQ, Foreman DJ, VanAernum ZL, Durr E, Wang S, Vlasak J, Galli J, Kafader JO, Tsukidate T, Li X, Schuessler HA, Richardson DD. Dissecting the Heterogeneous Glycan Profiles of Recombinant Coronavirus Spike Proteins with Individual Ion Mass Spectrometry. J Am Soc Mass Spectrom 2024; 35:62-73. [PMID: 38032172 DOI: 10.1021/jasms.3c00309] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/01/2023]
Abstract
Surface-embedded glycoproteins, such as the spike protein trimers of coronaviruses MERS, SARS-CoV, and SARS-CoV-2, play a key role in viral function and are the target antigen for many vaccines. However, their significant glycan heterogeneity poses an analytical challenge. Here, we utilized individual ion mass spectrometry (I2MS), a multiplexed charge detection measurement with similarities to charge detection mass spectrometry (CDMS), in which a commercially available Orbitrap analyzer is used to directly produce mass profiles of these heterogeneous coronavirus spike protein trimers under native-like conditions. Analysis by I2MS shows that glycosylation contributes to the molecular mass of each protein trimer more significantly than expected by bottom-up techniques, highlighting the importance of obtaining complementary intact mass information when characterizing glycosylation of such heterogeneous proteins. Enzymatic dissection to remove sialic acid or N-linked glycans demonstrates that I2MS can be used to better understand the glycan profile from a native viewpoint. Deglycosylation of N-glycans followed by I2MS analysis indicates that the SARS-CoV-2 spike protein trimer contains glycans that are more difficult to remove than its MERS and SARS-CoV counterparts, and these differences are correlated with solvent accessibility. I2MS technology enables characterization of protein mass and intact glycan profile and is orthogonal to traditional mass analysis methods such as size exclusion chromatography-multiangle light scattering (SEC-MALS) and field flow fractionation-multiangle light scattering (FFF-MALS). An added advantage of I2MS is low sample use, requiring 100-fold less than other methodologies. This work highlights how I2MS technology can enable efficient development of vaccines and therapeutics for pharmaceutical development.
Collapse
Affiliation(s)
- Alyssa Q Stiving
- Analytical Research and Development, Merck & Co., Inc., 126 E. Lincoln Avenue, Rahway, New Jersey 07065, United States
| | - David J Foreman
- Analytical Research and Development, Merck & Co., Inc., 126 E. Lincoln Avenue, Rahway, New Jersey 07065, United States
| | - Zachary L VanAernum
- Analytical Research and Development, Merck & Co., Inc., 126 E. Lincoln Avenue, Rahway, New Jersey 07065, United States
| | - Eberhard Durr
- Infectious Diseases and Vaccines Discovery, Merck & Co., Inc., West Point, Pennsylvania 19486, United States
| | - Shiyi Wang
- Analytical Research and Development, Merck & Co., Inc., 126 E. Lincoln Avenue, Rahway, New Jersey 07065, United States
| | - Josef Vlasak
- Analytical Research and Development, Merck & Co., Inc., 126 E. Lincoln Avenue, Rahway, New Jersey 07065, United States
| | - Jennifer Galli
- Infectious Diseases and Vaccines Discovery, Merck & Co., Inc., West Point, Pennsylvania 19486, United States
| | - Jared O Kafader
- Departments of Chemistry and Molecular Biosciences, The Chemistry of Life Processes Institute, The Proteomics Center of Excellence at Northwestern University, Evanston, Illinois 60208, United States
| | - Taku Tsukidate
- Analytical Research and Development, Merck & Co., Inc., 126 E. Lincoln Avenue, Rahway, New Jersey 07065, United States
| | - Xuanwen Li
- Analytical Research and Development, Merck & Co., Inc., 126 E. Lincoln Avenue, Rahway, New Jersey 07065, United States
| | - Hillary A Schuessler
- Analytical Research and Development, Merck & Co., Inc., 126 E. Lincoln Avenue, Rahway, New Jersey 07065, United States
| | - Douglas D Richardson
- Analytical Research and Development, Merck & Co., Inc., 126 E. Lincoln Avenue, Rahway, New Jersey 07065, United States
| |
Collapse
|
3
|
Liu Y, VanAernum Z, Zhang Y, Gao X, Vlad M, Feng B, Cross R, Kilgore B, Newman A, Wang D, Schuessler HA, Richardson DD, Chadwick JS. LC-MS Approach to Decipher a Light Chain Chromatographic Peak Splitting of a Monoclonal Antibody. Pharm Res 2023; 40:3087-3098. [PMID: 37936013 DOI: 10.1007/s11095-023-03631-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/11/2023] [Accepted: 10/20/2023] [Indexed: 11/09/2023]
Abstract
PURPOSE Monoclonal antibodies (mAbs), like other protein therapeutics, are prone to various forms of degradation, some of which are difficult to distinguish from the native form yet may alter potency. A generalizable LC-MS approach was developed to enable quantitative analysis of isoAsp. In-depth understanding of product quality attributes (PQAs) enables optimization of the manufacturing process, better formulation selection, and decreases risk associated with product handling in the clinic or during shipment. METHODS Reversed-phase chromatographic peak splitting was observed when a mAb was exposed to elevated temperatures. Multiple LC-MS based methods were applied to identify the reason for peak splitting. The approach involved the use of complementary HPLC columns, multiple enzymatic digestions and different MS/MS ion dissociation methods. In addition, mAb potency was measured by enzyme-linked immunosorbent assay (ELISA). RESULTS The split peaks had identical masses, and the root cause of the peak splitting was identified as isomerization of an aspartic acid located in the complementarity-determining region (CDR) of the light chain. And the early eluting and late eluting peaks were collected and performed enzymatic digestion to confirm the isoAsp enrichment in the early eluting peak. In addition, decreased potency was observed in the same heat-stressed sample, and the increased isoAsp levels in the CDR correlate well with a decrease of potency. CONCLUSION Liquid chromatography-mass spectrometry (LC-MS) has been utilized extensively to assess PQAs of biological therapeutics. In this study, a generalizable LC-MS-based approach was developed to enable identification and quantitation of the isoAsp-containing peptides.
Collapse
Affiliation(s)
- Yanjun Liu
- ProtaGene US, Inc. was Formerly BioAnalytix Inc., 4 Burlington Woods Dr., Burlington, MA, 01803, USA.
| | - Zac VanAernum
- Analytical Research & Development, Merck & Co., Inc., 126 E. Lincoln Ave, Rahway, NJ, 07065, USA.
| | - Yue Zhang
- ProtaGene US, Inc. was Formerly BioAnalytix Inc., 4 Burlington Woods Dr., Burlington, MA, 01803, USA
- Biogen, 225 Binney Street, Cambridge, MA, 02142, USA
| | - Xinliu Gao
- Analytical Research & Development, Merck & Co., Inc., 126 E. Lincoln Ave, Rahway, NJ, 07065, USA
| | - Mariana Vlad
- Analytical Research & Development, Merck & Co., Inc., 126 E. Lincoln Ave, Rahway, NJ, 07065, USA
| | - Bo Feng
- Analytical Research & Development, Merck & Co., Inc., 126 E. Lincoln Ave, Rahway, NJ, 07065, USA
| | - Robert Cross
- Analytical Research & Development, Merck & Co., Inc., 126 E. Lincoln Ave, Rahway, NJ, 07065, USA
| | - Bruce Kilgore
- Analytical Research & Development, Merck & Co., Inc., 126 E. Lincoln Ave, Rahway, NJ, 07065, USA
| | - Alice Newman
- Analytical Research & Development, Merck & Co., Inc., 126 E. Lincoln Ave, Rahway, NJ, 07065, USA
| | - Dongdong Wang
- ProtaGene US, Inc. was Formerly BioAnalytix Inc., 4 Burlington Woods Dr., Burlington, MA, 01803, USA
- Takeda Pharmaceutical Company, 35 Landsdowne St, Cambridge, MA, 02139, USA
| | - Hillary A Schuessler
- Analytical Research & Development, Merck & Co., Inc., 126 E. Lincoln Ave, Rahway, NJ, 07065, USA
| | - Douglas D Richardson
- Analytical Research & Development, Merck & Co., Inc., 126 E. Lincoln Ave, Rahway, NJ, 07065, USA
| | - Jennifer S Chadwick
- ProtaGene US, Inc. was Formerly BioAnalytix Inc., 4 Burlington Woods Dr., Burlington, MA, 01803, USA
| |
Collapse
|
4
|
Yan JX, Wu Q, Maity M, Braun DR, Alas I, Wang X, Yin X, Zhu Y, Bell BA, Rajski SR, Ge Y, Richardson DD, Zhong W, Bugni TS. Rapid Unambiguous Structure Elucidation of Streptnatamide A, a New Cyclic Peptide Isolated from A Marine-derived Streptomyces sp. Chemistry 2023; 29:e202301813. [PMID: 37452377 PMCID: PMC10592287 DOI: 10.1002/chem.202301813] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/15/2023] [Revised: 07/14/2023] [Accepted: 07/14/2023] [Indexed: 07/18/2023]
Abstract
Cyclic peptides have been excellent source of drug leads. With the advances in discovery platforms, the pharmaceutical industry has a growing interest in cyclic peptides and has pushed several into clinical trials. However, structural complexity of cyclic peptides brings extreme challenges for structure elucidation efforts. Isotopic fine structure analysis, Nuclear magnetic resonance (NMR), and detailed tandem mass spectrometry rapidly provided peptide sequence for streptnatamide A, a cyclic peptide isolated from a marine-derived Streptomyces sp. Marfey's analysis determined the stereochemistry of all amino acids, enabling the unambiguous structure determination of this compound. A non-ribosomal peptide synthetase biosynthetic gene cluster (stp) was tentatively identified and annotated for streptnatamide A based on the in silico analysis of whole genome sequencing data. These analytical tools will be powerful tools to overcome the challenges for cyclic peptide structure elucidation and accelerate the development of bioactive cyclic peptides.
Collapse
Affiliation(s)
- Jia-Xuan Yan
- Merck & Co., Inc., 126 E. Lincoln Ave, 07065, Rahway, NJ, USA
- Pharmaceutical Sciences Division, University of Wisconsin-Madison, 777 Highland Ave, 53705, Madison, WI, USA
| | - Qihao Wu
- Pharmaceutical Sciences Division, University of Wisconsin-Madison, 777 Highland Ave, 53705, Madison, WI, USA
- Current address: Department of Chemistry, Institute of Biomolecular Design & Discovery, Yale University, 06516, West Haven, CT, USA
| | - Mitasree Maity
- Pharmaceutical Sciences Division, University of Wisconsin-Madison, 777 Highland Ave, 53705, Madison, WI, USA
| | - Doug R Braun
- Pharmaceutical Sciences Division, University of Wisconsin-Madison, 777 Highland Ave, 53705, Madison, WI, USA
| | - Imraan Alas
- Pharmaceutical Sciences Division, University of Wisconsin-Madison, 777 Highland Ave, 53705, Madison, WI, USA
| | - Xiao Wang
- Merck & Co., Inc., 126 E. Lincoln Ave, 07065, Rahway, NJ, USA
| | - Xing Yin
- Merck & Co., Inc., 126 E. Lincoln Ave, 07065, Rahway, NJ, USA
| | - Yanlong Zhu
- Department of Cell and Regenerative Biology, University of Wisconsin-Madison, 1111 Highland Ave, 53705, Madison, WI, USA
- Human Proteomics Program, School of Medicine and Public Health, University of Wisconsin-Madison, 1111 Highland Ave, 53705, Madison, WI, USA
| | - Bailey A Bell
- Pharmaceutical Sciences Division, University of Wisconsin-Madison, 777 Highland Ave, 53705, Madison, WI, USA
| | - Scott R Rajski
- Pharmaceutical Sciences Division, University of Wisconsin-Madison, 777 Highland Ave, 53705, Madison, WI, USA
| | - Ying Ge
- Department of Cell and Regenerative Biology, University of Wisconsin-Madison, 1111 Highland Ave, 53705, Madison, WI, USA
- Human Proteomics Program, School of Medicine and Public Health, University of Wisconsin-Madison, 1111 Highland Ave, 53705, Madison, WI, USA
- Department of Chemistry, University of Wisconsin-Madison, 1101 University Ave, 53706, Madison, WI, USA
| | | | - Wendy Zhong
- Merck & Co., Inc., 126 E. Lincoln Ave, 07065, Rahway, NJ, USA
| | - Tim S Bugni
- Pharmaceutical Sciences Division, University of Wisconsin-Madison, 777 Highland Ave, 53705, Madison, WI, USA
- Lachman Institute for Pharmaceutical Development, University of Wisconsin-Madison, 600 Highland Ave, 53792, Madison, WI, USA
| |
Collapse
|
5
|
Li X, Pierson NA, Hua X, Patel BA, Olma MH, Strulson CA, Letarte S, Richardson DD. Analytical Performance Evaluation of Identity, Quality-Attribute Monitoring and new Peak Detection in a Platform Multi-Attribute Method Using Lys-C Digestion for Characterization and Quality Control of Therapeutic Monoclonal Antibodies. J Pharm Sci 2023; 112:691-699. [PMID: 36279953 DOI: 10.1016/j.xphs.2022.10.018] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/10/2022] [Revised: 10/15/2022] [Accepted: 10/15/2022] [Indexed: 11/06/2022]
Abstract
The use of multi-attribute method (MAM) for identity and purity testing of biopharmaceuticals offers the ability to complement and replace multiple conventional analytical technologies with a single mass spectrometry (MS) method. Phase-appropriate method validation is one major consideration for the implementation of MAM in a current Good Manufacturing Practice (cGMP) environment. We developed a MAM workflow for therapeutic monoclonal antibodies (mAbs) with optimized sample preparation using lysyl endopeptidase (Lys-C) digestion. In this study, we evaluated the assay performances of this platform MAM workflow for identity, product quality attributes (PQAs) monitoring and new peak detection (NPD) for single and coformulated mAbs. An IgG4 mAb-1 and its coformulations were used as model molecules in this study. The assay performance evaluation demonstrated the full potential of the platform MAM approach for its intended use for characterization and quality control of single mAb-1 and mAb-1 in its coformulations. To the best of our knowledge, this is the first performance evaluation of MAM for mAb identity, PQA monitoring, and new peak detection (NPD) in a single assay, featuring 1) the first performance evaluation of MAM for PQA monitoring using Lys-C digestion with a high-resolution MS, 2) a new approach for mAb identity testing capable of distinguishing single mAb from coformulations using MAM, and 3) the performance evaluation of NPD for MAM with Lys-C digestion. The developed platform MAM workflow and the MAM performance evaluation paved the way for its GMP qualification and enabled clinical release of mAb-1 in GMP environment with MAM.
Collapse
Affiliation(s)
- Xuanwen Li
- Analytical Research & Development, Merck & Co., Inc., 2000 Galloping Hill Road, Kenilworth, NJ 07033, United States.
| | - Nicholas A Pierson
- Analytical Research & Development, Merck & Co., Inc., 2000 Galloping Hill Road, Kenilworth, NJ 07033, United States
| | - Xiaoqing Hua
- Analytical Research & Development, Merck & Co., Inc., 2000 Galloping Hill Road, Kenilworth, NJ 07033, United States
| | - Bhumit A Patel
- Analytical Research & Development, Merck & Co., Inc., 2000 Galloping Hill Road, Kenilworth, NJ 07033, United States
| | - Michael H Olma
- Analytical Research & Development, Merck & Co., Inc., 2000 Galloping Hill Road, Kenilworth, NJ 07033, United States
| | - Christopher A Strulson
- Analytical Research & Development, Merck & Co., Inc., 2000 Galloping Hill Road, Kenilworth, NJ 07033, United States
| | - Simon Letarte
- Analytical Research & Development, Merck & Co., Inc., 2000 Galloping Hill Road, Kenilworth, NJ 07033, United States
| | - Douglas D Richardson
- Analytical Research & Development, Merck & Co., Inc., 2000 Galloping Hill Road, Kenilworth, NJ 07033, United States
| |
Collapse
|
6
|
Whitty-Léveillé L, VanAernum ZL, Pavon JA, Murphy C, Neal K, Forest W, Gao X, Zhong W, Richardson DD, Schuessler HA. Determination of ultra-trace metal-protein interactions in co-formulated monoclonal antibody drug product by SEC-ICP-MS. MAbs 2023; 15:2199466. [PMID: 37032437 PMCID: PMC10085571 DOI: 10.1080/19420862.2023.2199466] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/11/2023] Open
Abstract
Transition metals can be introduced in therapeutic protein drugs at various steps of the manufacturing process (e.g. manufacturing raw materials, formulation, storage), and can cause a variety of modifications on the protein. These modifications can potentially influence the efficacy, safety, and stability of the therapeutic protein, especially if critical quality attributes (CQAs) are affected. Therefore, it is meaningful to understand the interactions between proteins and metals that can occur during the manufacturing process, formulation, and storage of biotherapeutics. Here, we describe a novel strategy to differentiate between ultra-trace levels of transition metals (cobalt, chromium, copper, iron, and nickel) interacting with therapeutic proteins and free metal in solution in the drug formulation using size exclusion chromatography coupled to inductively coupled plasma mass spectrometry (SEC-ICP-MS). Two monoclonal antibodies (mAbs) were coformulated and stored up to nine days in a scaled down model to mimic metal exposure from manufacturing tanks. The samples containing the mAbs were first analyzed by ICP-MS for bulk metal analysis, then studied using SEC-ICP-MS to measure the extent of metal-protein interactions. The SEC separation was used to differentiate metal associated with the mAbs from free metal in solution. Relative quantitation of metal-protein interaction was then calculated using the relative peak areas of protein-associated metal to free metal in solution and weighting it to the total metal concentration in the mixture as measured by bulk metal analysis by ICP-MS. The SEC-ICP-MS method offers an informative means of measuring metal-protein interactions during drug development.
Collapse
Affiliation(s)
| | | | | | - Christa Murphy
- Analytical Research and Development, Merck & Co, Inc, Rahway, New Jersey
| | - Katie Neal
- Analytical Research and Development, Merck & Co, Inc, Rahway, New Jersey
| | - William Forest
- Analytical Research and Development, Merck & Co, Inc, Rahway, New Jersey
| | - Xinliu Gao
- Analytical Research and Development, Merck & Co, Inc, Rahway, New Jersey
| | - Wendy Zhong
- Analytical Research and Development, Merck & Co, Inc, Rahway, New Jersey
| | | | | |
Collapse
|
7
|
Espeseth AS, Yuan M, Citron M, Reiserova L, Morrow G, Wilson A, Horton M, Rukhman M, Kinek K, Hou F, Li SL, Li F, Choi Y, Heidecker G, Luo B, Wu G, Zhang L, Strable E, DeStefano J, Secore S, Mukhopadhyay TK, Richardson DD, Sayeed E, Welch LS, Bett AJ, Feinberg MB, Gupta SB, Cooper CL, Parks CL. Preclinical immunogenicity and efficacy of a candidate COVID-19 vaccine based on a vesicular stomatitis virus-SARS-CoV-2 chimera. EBioMedicine 2022; 82:104203. [PMID: 35915046 PMCID: PMC9338221 DOI: 10.1016/j.ebiom.2022.104203] [Citation(s) in RCA: 14] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/09/2021] [Revised: 07/22/2022] [Accepted: 07/22/2022] [Indexed: 12/17/2022] Open
Abstract
Background To investigate a vaccine technology with potential to protect against coronavirus disease 2019 (COVID-19) and reduce transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) with a single vaccine dose, we developed a SARS-CoV-2 candidate vaccine using the live vesicular stomatitis virus (VSV) chimeric virus approach previously used to develop a licensed Ebola virus vaccine. Methods We generated a replication-competent chimeric VSV-SARS-CoV-2 vaccine candidate by replacing the VSV glycoprotein (G) gene with coding sequence for the SARS-CoV-2 Spike glycoprotein (S). Immunogenicity of the lead vaccine candidate (VSV∆G-SARS-CoV-2) was evaluated in cotton rats and golden Syrian hamsters, and protection from SARS-CoV-2 infection also was assessed in hamsters. Findings VSV∆G-SARS-CoV-2 delivered with a single intramuscular (IM) injection was immunogenic in cotton rats and hamsters and protected hamsters from weight loss following SARS-CoV-2 challenge. When mucosal vaccination was evaluated, cotton rats did not respond to the vaccine, whereas mucosal administration of VSV∆G-SARS-CoV-2 was found to be more immunogenic than IM injection in hamsters and induced immunity that significantly reduced SARS-CoV-2 challenge virus loads in both lung and nasal tissues. Interpretation VSV∆G-SARS-CoV-2 delivered by IM injection or mucosal administration was immunogenic in golden Syrian hamsters, and both vaccination methods effectively protected the lung from SARS-CoV-2 infection. Hamsters vaccinated by mucosal application of VSV∆G-SARS-CoV-2 also developed immunity that controlled SARS-CoV-2 replication in nasal tissue. Funding The study was funded by Merck Sharp & Dohme, Corp., a subsidiary of Merck & Co., Inc., Rahway, NJ, USA, and The International AIDS Vaccine Initiative, Inc. (IAVI), New York, USA. Parts of this research was supported by the Biomedical Advanced Research and Development Authority (BARDA) and the Defense Threat Reduction Agency (DTRA) of the US Department of Defense.
Collapse
Affiliation(s)
| | - Maoli Yuan
- The International AIDS Vaccine Initiative, Inc. (IAVI), Vaccine Design and Development Laboratory, New York, USA
| | | | - Lucia Reiserova
- The International AIDS Vaccine Initiative, Inc. (IAVI), Vaccine Design and Development Laboratory, New York, USA
| | - Gavin Morrow
- The International AIDS Vaccine Initiative, Inc. (IAVI), Vaccine Design and Development Laboratory, New York, USA
| | - Aaron Wilson
- The International AIDS Vaccine Initiative, Inc. (IAVI), Vaccine Design and Development Laboratory, New York, USA
| | | | - Mark Rukhman
- The International AIDS Vaccine Initiative, Inc. (IAVI), Vaccine Design and Development Laboratory, New York, USA
| | | | - Fuxiang Hou
- The International AIDS Vaccine Initiative, Inc. (IAVI), Vaccine Design and Development Laboratory, New York, USA
| | - Shui L Li
- The International AIDS Vaccine Initiative, Inc. (IAVI), Vaccine Design and Development Laboratory, New York, USA
| | | | - Yesle Choi
- The International AIDS Vaccine Initiative, Inc. (IAVI), Vaccine Design and Development Laboratory, New York, USA
| | | | - Bin Luo
- Merck & Co., Inc., Rahway, New Jersey, USA
| | - Guoxin Wu
- Merck & Co., Inc., Rahway, New Jersey, USA
| | - Lan Zhang
- Merck & Co., Inc., Rahway, New Jersey, USA
| | | | - Joanne DeStefano
- The International AIDS Vaccine Initiative, Inc. (IAVI), Vaccine Design and Development Laboratory, New York, USA
| | | | | | | | - Eddy Sayeed
- The International AIDS Vaccine Initiative, Inc. (IAVI), New York, USA
| | - Lisa S Welch
- The International AIDS Vaccine Initiative, Inc. (IAVI), New York, USA; Currently at Clover Biopharmaceuticals, Boston, Massachusetts, USA
| | | | - Mark B Feinberg
- The International AIDS Vaccine Initiative, Inc. (IAVI), New York, USA
| | - Swati B Gupta
- The International AIDS Vaccine Initiative, Inc. (IAVI), New York, USA
| | - Christopher L Cooper
- The International AIDS Vaccine Initiative, Inc. (IAVI), Vaccine Design and Development Laboratory, New York, USA
| | - Christopher L Parks
- The International AIDS Vaccine Initiative, Inc. (IAVI), Vaccine Design and Development Laboratory, New York, USA.
| |
Collapse
|
8
|
Li X, Rawal B, Rivera S, Letarte S, Richardson DD. Improvements on sample preparation and peptide separation for reduced peptide mapping based multi-attribute method analysis of therapeutic monoclonal antibodies using lysyl endopeptidase digestion. J Chromatogr A 2022; 1675:463161. [DOI: 10.1016/j.chroma.2022.463161] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/11/2022] [Revised: 05/17/2022] [Accepted: 05/18/2022] [Indexed: 12/14/2022]
|
9
|
Graf A, Woodhams A, Nelson M, Richardson DD, Short SM, Brower M, Hoehse M. Automated Data Generation for Raman Spectroscopy Calibrations in Multi-Parallel Mini Bioreactors. Sensors 2022; 22:s22093397. [PMID: 35591088 PMCID: PMC9099804 DOI: 10.3390/s22093397] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 03/06/2022] [Revised: 04/20/2022] [Accepted: 04/27/2022] [Indexed: 02/04/2023]
Abstract
Raman spectroscopy is an analytical technology for the simultaneous measurement of important process parameters, such as concentrations of nutrients, metabolites, and product titer in mammalian cell culture. The majority of published Raman studies have concentrated on using the technique for the monitoring and control of bioreactors at pilot and manufacturing scales. This research presents a novel approach to generating Raman models using a high-throughput 250 mL mini bioreactor system with the following two integrated analysis modules: a prototype flow cell enabling on-line Raman measurements and a bioanalyzer to generate reference measurements without a significant time-shift, compared to the corresponding Raman measurement. Therefore, spectral variations could directly be correlated with the actual analyte concentrations to build reliable models. Using a design of experiments (DoE) approach and additional spiked samples, the optimized workflow resulted in robust Raman models for glucose, lactate, glutamine, glutamate and titer in Chinese hamster ovary (CHO) cell cultures producing monoclonal antibodies (mAb). The setup presented in this paper enables the generation of reliable Raman models that can be deployed to predict analyte concentrations, thereby facilitating real-time monitoring and control of biologics manufacturing.
Collapse
Affiliation(s)
- Alexander Graf
- Sartorius Stedim Biotech GmbH, August-Spindler-Straße 11, 37079 Goettingen, Germany;
| | | | - Michael Nelson
- Merck & Co., Inc., 2000 Galloping Hill Rd., Kenilworth, NJ 07033, USA; (M.N.); (D.D.R.); (S.M.S.); (M.B.)
| | - Douglas D. Richardson
- Merck & Co., Inc., 2000 Galloping Hill Rd., Kenilworth, NJ 07033, USA; (M.N.); (D.D.R.); (S.M.S.); (M.B.)
| | - Steven M. Short
- Merck & Co., Inc., 2000 Galloping Hill Rd., Kenilworth, NJ 07033, USA; (M.N.); (D.D.R.); (S.M.S.); (M.B.)
| | - Mark Brower
- Merck & Co., Inc., 2000 Galloping Hill Rd., Kenilworth, NJ 07033, USA; (M.N.); (D.D.R.); (S.M.S.); (M.B.)
| | - Marek Hoehse
- Sartorius Stedim Biotech GmbH, August-Spindler-Straße 11, 37079 Goettingen, Germany;
- Correspondence:
| |
Collapse
|
10
|
Li X, Wang F, Li H, Richardson DD, Roush DJ. The measurement and control of high-risk host cell proteins for polysorbate degradation in biologics formulation. Antib Ther 2022; 5:42-54. [PMID: 35155990 PMCID: PMC8826928 DOI: 10.1093/abt/tbac002] [Citation(s) in RCA: 9] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/04/2021] [Revised: 12/21/2021] [Accepted: 01/02/2022] [Indexed: 11/13/2022] Open
Abstract
Nonionic surfactant polysorbates, including PS-80 and PS-20, are commonly used in the formulation of biotherapeutic products for both preventing surface adsorption and acting as stabilizer against protein aggregation. Trace levels of residual host cell proteins (HCPs) with lipase or esterase enzymatic activity have been shown to degrade polysorbates in biologics formulation. The measurement and control of these low abundance, high-risk HCPs for polysorbate degradation are an industry-wide challenge to achieve desired shelf life of biopharmaceuticals in liquid formulation, especially for high-concentration formulation product development. Here, we reviewed the challenges, recent advances, and future opportunities of analytical method development, risk assessment, and control strategies for polysorbate degradation during formulation development with a focus on enzymatic degradation. Continued efforts to advance our understanding of polysorbate degradation in biologics formulation will help develop high-quality medicines for patients.
Collapse
Affiliation(s)
- Xuanwen Li
- Analytical Research & Development, Merck & Co., Inc., 2000 Galloping Hill Road, Kenilworth, NJ 07033, USA
- To whom correspondence should be addressed: Xuanwen Li, Analytical Research & Development Mass Spectrometry, Merck & Co. Inc., 770 Sumneytown Pike, WPP042A-4015, West Point, PA 19486. Tel: 215-652-1829;
| | - Fengqiang Wang
- Analytical Research & Development, Merck & Co., Inc., 2000 Galloping Hill Road, Kenilworth, NJ 07033, USA
| | - Hong Li
- Biologics Process Research & Development, Merck & Co., Inc., 2000 Galloping Hill Road, Kenilworth, NJ 07033, USA
| | - Douglas D Richardson
- Analytical Research & Development, Merck & Co., Inc., 2000 Galloping Hill Road, Kenilworth, NJ 07033, USA
| | - David J Roush
- Biologics Process Research & Development, Merck & Co., Inc., 2000 Galloping Hill Road, Kenilworth, NJ 07033, USA
| |
Collapse
|
11
|
Bennett R, Cohen RD, Wang H, Pereira T, Haverick MA, Loughney JW, Barbacci DC, Pristatsky P, Bowman AM, Losacco GL, Richardson DD, Mangion I, Regalado EL. Selective Plate-Based Assay for Trace EDTA Analysis via Boron Trifluoride-methanol Derivatization UHPLC-QqQ-MS/MS Enabling Biologic and Vaccine Processes. Anal Chem 2021; 94:1678-1685. [PMID: 34928586 DOI: 10.1021/acs.analchem.1c04224] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
The employment of ethylenediaminetetraacetic acid (EDTA) across several fields in chemistry and biology has required the creation of a high number of quantitative assays. Nonetheless, the determination of trace EDTA, especially in biologics and vaccines, remains challenging. Herein, we introduce an automated high-throughput approach based on EDTA esterification in 96-well plates using boron trifluoride-methanol combined with rapid analysis by ultra-high-performance liquid chromatography-triple quadrupole tandem mass spectrometry (UHPLC-QqQ-MS/MS). Derivatization of EDTA to its methyl ester (Me-EDTA) serves to significantly improve chromatographic performance (retention, peak shape, and selectivity), while also delivering a tremendous enhancement of sensitivity in the positive ion mode electrospray ionization (ESI+). This procedure, in contrast to previous EDTA methods based on complexation with metal ions, is not affected by high concentration of other metals, buffers, and related salts abundantly present in biopharmaceutical processes (e.g., iron, copper, citrate, etc.). Validation of this assay for the determination of ng·mL-1 level EDTA in monoclonal antibody and vaccine products demonstrated excellent performance (repeatability, precision, and linear range) with high recovery from small sample volumes while also providing an advantageous automation-friendly workflow for high-throughput analysis.
Collapse
Affiliation(s)
- Raffeal Bennett
- Analytical Research & Development, Merck & Co. Inc., West Point, Pennsylvania 19486, United States
| | - Ryan D Cohen
- Analytical Research & Development, MRL, Merck & Co., Inc., Rahway, New Jersey 07065, United States
| | - Heather Wang
- Analytical Research & Development, MRL, Merck & Co., Inc., Rahway, New Jersey 07065, United States
| | - Tony Pereira
- Transporters & In Vitro Technologies, PPDM, MRL, Merck & Co., Inc., Rahway, New Jersey 07065, United States
| | - Mark A Haverick
- Analytical Research & Development, Merck & Co. Inc., West Point, Pennsylvania 19486, United States
| | - John W Loughney
- Analytical Research & Development, Merck & Co. Inc., West Point, Pennsylvania 19486, United States
| | - Damon C Barbacci
- Analytical Research & Development, Merck & Co. Inc., West Point, Pennsylvania 19486, United States
| | - Pavlo Pristatsky
- Analytical Research & Development, Merck & Co. Inc., West Point, Pennsylvania 19486, United States
| | - Amy M Bowman
- Analytical Research & Development, Merck & Co. Inc., West Point, Pennsylvania 19486, United States
| | - Gioacchino Luca Losacco
- Analytical Research & Development, MRL, Merck & Co., Inc., Rahway, New Jersey 07065, United States
| | - Douglas D Richardson
- Analytical Research & Development, Merck & Co. Inc., West Point, Pennsylvania 19486, United States
| | - Ian Mangion
- Analytical Research & Development, MRL, Merck & Co., Inc., Rahway, New Jersey 07065, United States
| | - Erik L Regalado
- Analytical Research & Development, MRL, Merck & Co., Inc., Rahway, New Jersey 07065, United States
| |
Collapse
|
12
|
Ralbovsky NM, Soukup RJ, Lomont JP, Lauro ML, Gulasarian A, Saha-Shah A, Winters MA, Richardson DD, Wang SC, Mangion I, Smith JP. In situ real time monitoring of emulsification and homogenization processes for vaccine adjuvants. Analyst 2021; 147:378-386. [PMID: 34908043 DOI: 10.1039/d1an01797g] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
Adjuvants are commonly employed to enhance the efficacy of a vaccine and thereby increase the resulting immune response in a patient. The activity and effectiveness of emulsion-based adjuvants has been heavily studied throughout pharmaceuticals; however, there exists a lack in research which monitors the formation of a stable emulsion in real time. Process analytical technology (PAT) provides a solution to meet this need. PAT involves the collection of in situ data, thereby providing real time information about the monitored process as well as increasing understanding of that process. Here, three separate PAT tools - optical particle imaging, in situ particle analysis, and Raman spectroscopy - were used to monitor two key steps involved in the formation of a stable emulsion product, emulsification and homogenization, as well as perform a stability assessment. The obtained results provided new insights-particle size decreases during emulsification and homogenization, and molecular changes do not occur during either the emulsification or homogenization steps. Further, the stability assessment indicated that the coarse emulsion product obtained from the emulsification step is stable over the course of 24 hours when mixed. To the best of our knowledge, this is the first report of an analytical methodology for in situ, real time analysis of emulsification and homogenization processes for vaccine adjuvants. Using our proposed analytical methodology, an improved understanding of emulsion-based vaccine adjuvants can now be achieved, ultimately impacting the ability to develop and deliver successful pharmaceuticals.
Collapse
Affiliation(s)
- Nicole M Ralbovsky
- Analytical Research & Development, MRL, Merck & Co., Inc., West Point, PA 19486, USA.
| | - Randal J Soukup
- Process Research & Development, MRL, Merck & Co., Inc., West Point, PA, 19486, USA
| | - Justin P Lomont
- Analytical Research & Development, MRL, Merck & Co., Inc., West Point, PA 19486, USA.
| | - Mackenzie L Lauro
- Analytical Research & Development, MRL, Merck & Co., Inc., West Point, PA 19486, USA.
| | - Amanda Gulasarian
- Process Research & Development, MRL, Merck & Co., Inc., West Point, PA, 19486, USA
| | - Anumita Saha-Shah
- Analytical Research & Development, MRL, Merck & Co., Inc., West Point, PA 19486, USA.
| | - Michael A Winters
- Process Research & Development, MRL, Merck & Co., Inc., West Point, PA, 19486, USA
| | - Douglas D Richardson
- Analytical Research & Development, MRL, Merck & Co., Inc., West Point, PA 19486, USA.
| | - Sheng-Ching Wang
- Process Research & Development, MRL, Merck & Co., Inc., West Point, PA, 19486, USA
| | - Ian Mangion
- Analytical Research & Development, MRL, Merck & Co., Inc., West Point, PA 19486, USA.
| | - Joseph P Smith
- Analytical Research & Development, MRL, Merck & Co., Inc., West Point, PA 19486, USA.
| |
Collapse
|
13
|
Li X, Chandra D, Letarte S, Adam GC, Welch J, Yang RS, Rivera S, Bodea S, Dow A, Chi A, Strulson CA, Richardson DD. Profiling Active Enzymes for Polysorbate Degradation in Biotherapeutics by Activity-Based Protein Profiling. Anal Chem 2021; 93:8161-8169. [PMID: 34032423 DOI: 10.1021/acs.analchem.1c00042] [Citation(s) in RCA: 23] [Impact Index Per Article: 7.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022]
Abstract
Polysorbate is widely used to maintain stability of biotherapeutic proteins in pharmaceutical formulation development. Degradation of polysorbate can lead to particle formation in drug products, which is a major quality concern and potential patient risk factor. Enzymatic activity from residual host cell enzymes such as lipases and esterases plays a major role for polysorbate degradation. Their high activity, often at very low concentration, constitutes a major analytical challenge in the biopharmaceutical industry. In this study, we evaluated and optimized the activity-based protein profiling (ABPP) approach to identify active enzymes responsible for polysorbate degradation. Using an optimized chemical probe, we established the first global profile of active serine hydrolases in harvested cell culture fluid (HCCF) for monoclonal antibodies (mAbs) production from two Chinese hamster ovary (CHO) cell lines. A total of eight known lipases were identified by ABPP with enzyme activity information, while only five lipases were identified by a traditional abundance-based proteomics (TABP) approach. Interestingly, phospholipase B-like 2 (PLBL2), a well-known problematic HCP was not found to be active in process-intermediates from two different mAbs. In a proof-of-concept study with downstream samples, phospholipase A2 group VII (PLA2G7) was only identified by ABPP and confirmed to contribute to polysorbate-80 degradation for the first time. The established ABBP approach is approved to be able to identify low-abundance host cell enzymes and fills the gap between lipase abundance and activity, which enables more meaningful polysorbate degradation investigations for biotherapeutic development.
Collapse
Affiliation(s)
- Xuanwen Li
- Analytical Research & Development Mass Spectrometry, Merck & Co., Inc., 2000 Galloping Hill Road, Kenilworth, New Jersey 07033, United States
| | - Divya Chandra
- Biologics Process Research & Development, Merck & Co., Inc., 2000 Galloping Hill Road, Kenilworth, New Jersey 07033, United States
| | - Simon Letarte
- Analytical Research & Development Mass Spectrometry, Merck & Co., Inc., 2000 Galloping Hill Road, Kenilworth, New Jersey 07033, United States
| | - Gregory C Adam
- Quantitative Biosciences, Merck & Co., Inc., 770 Sumneytown Pike, West Point, Pennsylvania 19486, United States
| | - Jonathan Welch
- Biologics Analytical Research & Development, Merck & Co., Inc., 2000 Galloping Hill Road, Kenilworth, New Jersey 07033, United States
| | - Rong-Sheng Yang
- Analytical Research & Development Mass Spectrometry, Merck & Co., Inc., 2000 Galloping Hill Road, Kenilworth, New Jersey 07033, United States
| | - Shannon Rivera
- Analytical Research & Development Mass Spectrometry, Merck & Co., Inc., 2000 Galloping Hill Road, Kenilworth, New Jersey 07033, United States
| | - Smaranda Bodea
- Chemical Biology, Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts 02115, United States
| | - Alex Dow
- Biologics Analytical Research & Development, Merck & Co., Inc., 2000 Galloping Hill Road, Kenilworth, New Jersey 07033, United States
| | - An Chi
- Chemical Biology, Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts 02115, United States
| | - Christopher A Strulson
- Biologics Analytical Research & Development, Merck & Co., Inc., 2000 Galloping Hill Road, Kenilworth, New Jersey 07033, United States
| | - Douglas D Richardson
- Analytical Research & Development Mass Spectrometry, Merck & Co., Inc., 2000 Galloping Hill Road, Kenilworth, New Jersey 07033, United States
| |
Collapse
|
14
|
Rincon Pabon JP, Kochert BA, Liu YH, Richardson DD, Weis DD. Protein A does not induce allosteric structural changes in an IgG1 antibody during binding. J Pharm Sci 2021; 110:2355-2361. [PMID: 33640336 DOI: 10.1016/j.xphs.2021.02.027] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/18/2020] [Revised: 02/22/2021] [Accepted: 02/23/2021] [Indexed: 10/22/2022]
Abstract
Affinity chromatography is widely used for antibody purification in biopharmaceutical production. Although there is evidence suggesting that affinity chromatography might induce structural changes in antibodies, allosteric changes in structure have not been well-explored. Here, we used hydrogen exchange-mass spectrometry (HX-MS) to reveal conformational changes in the NIST mAb upon binding with a protein A (ProA) matrix. HX-MS measurements of NIST mAb bound to in-solution and resin forms of ProA revealed regions of the CH2 and CH3 domains with increased protection from HX upon ProA binding, consistent with the known ProA binding region. In-solution ProA experiments revealed regions in the Fab with increased HX uptake when the ProA:mAb molar ratio was increased to 2:1, suggesting an allosterically induced increase in backbone flexibility. Such effects were not observed with lower ProA concentration (1:1 molar ratio) or when ProA resin was used, suggesting some kind of change in binding mode. Since all pharmaceutical processes use ProA bound to resin, our results rule out reversible allosteric effects on the NIST mAb during interaction with resin ProA. However, irreversible effects cannot be ruled out since the NIST mAb was previously exposed to ProA during its original purification.
Collapse
Affiliation(s)
- Juan P Rincon Pabon
- Department of Chemistry and the Ralph N. Adams Institute for Bioanalytical Chemistry, University of Kansas, Lawrence, KS, United States
| | - Brent A Kochert
- Analytical Research & Development Mass Spectrometry, Merck & Co., Inc., Kenilworth, NJ, USA
| | - Yan-Hui Liu
- Analytical Research & Development Mass Spectrometry, Merck & Co., Inc., Kenilworth, NJ, USA
| | - Douglas D Richardson
- Analytical Research & Development Mass Spectrometry, Merck & Co., Inc., Kenilworth, NJ, USA
| | - David D Weis
- Department of Chemistry and the Ralph N. Adams Institute for Bioanalytical Chemistry, University of Kansas, Lawrence, KS, United States.
| |
Collapse
|
15
|
Li X, An Y, Liao J, Xiao L, Swanson M, Martinez-Fonts K, Pavon JA, Sherer EC, Jawa V, Wang F, Gao X, Letarte S, Richardson DD. Identification and characterization of a residual host cell protein hexosaminidase B associated with N-glycan degradation during the stability study of a therapeutic recombinant monoclonal antibody product. Biotechnol Prog 2021; 37:e3128. [PMID: 33476097 PMCID: PMC8365702 DOI: 10.1002/btpr.3128] [Citation(s) in RCA: 17] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/27/2020] [Revised: 12/22/2020] [Accepted: 01/12/2021] [Indexed: 12/30/2022]
Abstract
Host cell proteins (HCPs) are process‐related impurities derived from host organisms, which need to be controlled to ensure adequate product quality and safety. In this study, product quality attributes were tracked for several monoclonal antibodies (mAbs) under the intended storage and accelerated stability conditions. One product quality attribute not expected to be stability indicating is the N‐glycan heterogeneity profile. However, significant N‐glycan degradation was observed for one mAb under accelerated and stressed stability conditions. The root cause for this instability was attributed to hexosaminidase B (HEXB), an enzyme known to remove terminal N‐acetylglucosamine (GlcNAc). HEXB was identified by liquid chromatography–mass spectrometry (LC–MS)‐based proteomics approach to be enriched in the impacted stability batches from mAb‐1. Subsequently, enzymatic and targeted multiple reaction monitoring (MRM) MS assays were developed to support process and product characterization. A potential interaction between HEXB and mAb‐1 was initially observed from the analysis of process intermediates by proteomics among several mAbs and later supported by computational modeling. An improved bioprocess was developed to significantly reduce HEXB levels in the final drug substance. A risk assessment was conducted by evaluating the in silico immunogenicity risk and the impact on product quality. To the best of our knowledge, HEXB is the first residual HCP reported to have impact on the glycan profile of a formulated drug product. The combination of different analytical tools, mass spectrometry, and computational modeling provides a general strategy on how to study residual HCP for biotherapeutics development.
Collapse
Affiliation(s)
- Xuanwen Li
- Analytical Research & Development Mass Spectrometry, Merck & Co., Inc., Kenilworth, New Jersey, USA
| | - Yan An
- Biologics Analytical Research & Development, Merck & Co., Inc., Kenilworth, New Jersey, USA
| | - Jing Liao
- Analytical Research & Development Mass Spectrometry, Merck & Co., Inc., Kenilworth, New Jersey, USA
| | - Li Xiao
- Computational and Structural Chemistry, Merck & Co., Inc., Kenilworth, New Jersey, USA
| | - Michael Swanson
- Predictive and Clinical Immunogenicity, Merck & Co., Inc., Kenilworth, New Jersey, USA
| | - Kirby Martinez-Fonts
- Biologics Analytical Research & Development, Merck & Co., Inc., Kenilworth, New Jersey, USA
| | - Jorge Alexander Pavon
- Biologics Analytical Research & Development, Merck & Co., Inc., Kenilworth, New Jersey, USA
| | - Edward C Sherer
- Computational and Structural Chemistry, Merck & Co., Inc., Kenilworth, New Jersey, USA
| | - Vibha Jawa
- Predictive and Clinical Immunogenicity, Merck & Co., Inc., Kenilworth, New Jersey, USA
| | - Fengqiang Wang
- Biologics Analytical Research & Development, Merck & Co., Inc., Kenilworth, New Jersey, USA
| | - Xinliu Gao
- Analytical Research & Development Mass Spectrometry, Merck & Co., Inc., Kenilworth, New Jersey, USA
| | - Simon Letarte
- Analytical Research & Development Mass Spectrometry, Merck & Co., Inc., Kenilworth, New Jersey, USA
| | - Douglas D Richardson
- Analytical Research & Development Mass Spectrometry, Merck & Co., Inc., Kenilworth, New Jersey, USA
| |
Collapse
|
16
|
Dunn ZD, Desai J, Leme GM, Stoll DR, Richardson DD. Rapid two-dimensional Protein-A size exclusion chromatography of monoclonal antibodies for titer and aggregation measurements from harvested cell culture fluid samples. MAbs 2021; 12:1702263. [PMID: 31876441 PMCID: PMC6973321 DOI: 10.1080/19420862.2019.1702263] [Citation(s) in RCA: 21] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/23/2023] Open
Abstract
The success of monoclonal antibody (mAb) therapeutics have increased pharmaceutical investment in mAb production, which has led to a greater demand of technologies to efficiently characterize these biotherapeutics. The large size and heterogeneity of mAbs require the measurement of multiple critical quality attributes (CQAs) during production. The current workflow to measure CQAs of antibodies involves multiple one-dimensional liquid chromatography methods, including Protein-A (ProA), ion-exchange (IEX), reversed-phase, size exclusion (SEC), hydrophilic interaction, and hydrophobic interaction (HIC). Recent advances in commercial two-dimensional liquid chromatography (2D-LC) affords an opportunity to perform two separations at once to measure multiple CQAs in a single assay. Here, we describe the development of a 2D ProA–SEC method using entirely commercially available instrumentation. Each individual separation and the transfer of material between dimensions were optimized to develop a method that measures titer and aggregation of a target antibody from harvested cell culture fluid in under 5 min. We determined the effects of each parameter of the method on mAb recovery and stability, as well as speed, robustness, resolution, and accuracy of the aggregate amount detected in the second dimension (2D). While there are still sources of error caused by hardware limitations, our rapid ProA-SEC method is an effective screening tool with a significant throughput advantage over previously described methods. Additionally, this work serves as a basis for developing other 2D-LC methods with ProA as the first dimension (1D) separation coupled with different 2D separation, such as ProA-IEX and ProA-HIC.
Collapse
Affiliation(s)
- Zachary D Dunn
- Analytical Research and Development, Merck & Co. Inc., Kenilworth, NJ, USA
| | - Jayesh Desai
- Process Research and Development, Merck & Co. Inc., Kenilworth, NJ, USA
| | - Gabriel M Leme
- Department of Chemistry, Gustavus Adolphus College, St. Peter, MN, USA
| | - Dwight R Stoll
- Department of Chemistry, Gustavus Adolphus College, St. Peter, MN, USA
| | | |
Collapse
|
17
|
Wang L, Trang HK, Desai J, Dunn ZD, Richardson DD, Marcus RK. Fiber-based HIC capture loop for coupling of protein A and size exclusion chromatography in a two-dimensional separation of monoclonal antibodies. Anal Chim Acta 2020; 1098:190-200. [DOI: 10.1016/j.aca.2019.11.023] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/11/2019] [Revised: 11/05/2019] [Accepted: 11/08/2019] [Indexed: 11/28/2022]
|
18
|
Gao X, Rawal B, Wang Y, Li X, Wylie D, Liu YH, Breunig L, Driscoll D, Wang F, Richardson DD. Targeted Host Cell Protein Quantification by LC-MRM Enables Biologics Processing and Product Characterization. Anal Chem 2019; 92:1007-1015. [PMID: 31860266 DOI: 10.1021/acs.analchem.9b03952] [Citation(s) in RCA: 25] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
Abstract
Multiple reaction monitoring (MRM) is a liquid chromatography-mass spectrometry (LC-MS) based quantification platform with high sensitivity, specificity, and throughput. It is extensively used across the pharmaceutical industry for the quantitative analysis of therapeutic molecules. The potential of MRM analysis for the quantification of specific host cell proteins (HCPs) in bioprocess, however, has yet to be well established. In this work, we introduce a multiplex LC-MRM assay that simultaneously monitors two high risk lipases known to impact biologics product quality, Phospholipase B-like 2 protein (PLBL2) and Group XV lysosomal phospholipase A2 (LPLA2). Quantitative data generated from the LC-MRM assay were used to monitor the clearance of these lipases during biologics process development. The method is linear over a dynamic range of 1 to 500 ng/mg. To demonstrate the fitness for use and robustness of this assay, we evaluate a comprehensive method qualification package that includes intra- and inter-run precision and accuracy across all evaluated concentrations, selectivity, recovery and matrix effect, dilution linearity, and carryover. Additionally, we illustrate that this assay provides a rapid and accurate means of monitoring high risk HCP clearance for in-process support and can actively guide process improvement and optimization. Lastly, we compare direct digestion platforms and affinity depletion platforms to demonstrate the impact of HCP-mAb interaction on lipase quantification.
Collapse
Affiliation(s)
- Xinliu Gao
- Analytical Research & Development Mass Spectrometry , Merck & Company Incorporated , 2000 Galloping Hill Road , Kenilworth , New Jersey 07033 , United States
| | - Baibhav Rawal
- Analytical Research & Development Mass Spectrometry , Merck & Company Incorporated , 2000 Galloping Hill Road , Kenilworth , New Jersey 07033 , United States
| | - Yi Wang
- Analytical Research & Development Mass Spectrometry , Merck & Company Incorporated , 2000 Galloping Hill Road , Kenilworth , New Jersey 07033 , United States
| | - Xuanwen Li
- Analytical Research & Development Mass Spectrometry , Merck & Company Incorporated , 2000 Galloping Hill Road , Kenilworth , New Jersey 07033 , United States
| | - David Wylie
- Biologics Analytical Research & Development , Merck & Company Incorporated , 2000 Galloping Hill Road , Kenilworth , New Jersey 07033 , United States
| | - Yan-Hui Liu
- Analytical Research & Development Mass Spectrometry , Merck & Company Incorporated , 2000 Galloping Hill Road , Kenilworth , New Jersey 07033 , United States
| | - Lloyd Breunig
- Biologics Analytical Research & Development , Merck & Company Incorporated , 2000 Galloping Hill Road , Kenilworth , New Jersey 07033 , United States
| | - Dennis Driscoll
- Biologics Analytical Research & Development , Merck & Company Incorporated , 2000 Galloping Hill Road , Kenilworth , New Jersey 07033 , United States
| | - Fengqiang Wang
- Biologics Analytical Research & Development , Merck & Company Incorporated , 2000 Galloping Hill Road , Kenilworth , New Jersey 07033 , United States
| | - Douglas D Richardson
- Analytical Research & Development Mass Spectrometry , Merck & Company Incorporated , 2000 Galloping Hill Road , Kenilworth , New Jersey 07033 , United States
| |
Collapse
|
19
|
Patel BA, Gospodarek A, Larkin M, Kenrick SA, Haverick MA, Tugcu N, Brower MA, Richardson DD. Multi-angle light scattering as a process analytical technology measuring real-time molecular weight for downstream process control. MAbs 2018; 10:945-950. [PMID: 30130442 PMCID: PMC6204791 DOI: 10.1080/19420862.2018.1505178] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
Abstract
For many protein therapeutics including monoclonal antibodies, aggregate removal process can be complex and challenging. We evaluated two different process analytical technology (PAT) applications that couple a purification unit performing preparative hydrophobic interaction chromatography (HIC) to a multi-angle light scattering (MALS) system. Using first principle measurements, the MALS detector calculates weight-average molar mass, Mw and can control aggregate levels in purification. The first application uses an in-line MALS to send start/stop fractionation trigger signals directly to the purification unit when preset Mw criteria are met or unmet. This occurs in real-time and eliminates the need for analysis after purification. The second application uses on-line ultra-high performance size-exclusion liquid chromatography to sample from the purification stream, separating the mAb species and confirming their Mw using a µMALS detector. The percent dimer (1.5%) determined by the on-line method is in agreement with the data from the in-line application (Mw increase of approximately 2750 Da). The novel HIC-MALS systems demonstrated here can be used as a powerful tool for real-time aggregate monitoring and control during biologics purification enabling future real time release of biotherapeutics.
Collapse
Affiliation(s)
- Bhumit A Patel
- a Biologics Process Development and Clinical Manufacturing , Merck & Co., Inc ., Kenilworth , NJ , USA
| | - Adrian Gospodarek
- a Biologics Process Development and Clinical Manufacturing , Merck & Co., Inc ., Kenilworth , NJ , USA
| | - Michael Larkin
- b Wyatt Technology Corporation , Santa Barbara , CA , USA
| | | | - Mark A Haverick
- a Biologics Process Development and Clinical Manufacturing , Merck & Co., Inc ., Kenilworth , NJ , USA
| | - Nihal Tugcu
- a Biologics Process Development and Clinical Manufacturing , Merck & Co., Inc ., Kenilworth , NJ , USA
| | - Mark A Brower
- a Biologics Process Development and Clinical Manufacturing , Merck & Co., Inc ., Kenilworth , NJ , USA
| | - Douglas D Richardson
- a Biologics Process Development and Clinical Manufacturing , Merck & Co., Inc ., Kenilworth , NJ , USA
| |
Collapse
|
20
|
Rogers RS, Abernathy M, Richardson DD, Rouse JC, Sperry JB, Swann P, Wypych J, Yu C, Zang L, Deshpande R. A View on the Importance of “Multi-Attribute Method” for Measuring Purity of Biopharmaceuticals and Improving Overall Control Strategy. AAPS J 2017; 20:7. [DOI: 10.1208/s12248-017-0168-3] [Citation(s) in RCA: 78] [Impact Index Per Article: 11.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/02/2017] [Accepted: 11/08/2017] [Indexed: 11/30/2022]
|
21
|
Patel BA, Pinto ND, Gospodarek A, Kilgore B, Goswami K, Napoli WN, Desai J, Heo JH, Panzera D, Pollard D, Richardson D, Brower M, Richardson DD. On-Line Ion Exchange Liquid Chromatography as a Process Analytical Technology for Monoclonal Antibody Characterization in Continuous Bioprocessing. Anal Chem 2017; 89:11357-11365. [DOI: 10.1021/acs.analchem.7b02228] [Citation(s) in RCA: 40] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Affiliation(s)
- Bhumit A. Patel
- Biologics & Vaccines, Bioprocess Research and Development, Merck & Co., Inc., 2000 Galloping Hill Rd, Kenilworth, New Jersey 07033, United States
| | - Nuno D.S. Pinto
- Biologics & Vaccines, Bioprocess Research and Development, Merck & Co., Inc., 2000 Galloping Hill Rd, Kenilworth, New Jersey 07033, United States
| | - Adrian Gospodarek
- Biologics & Vaccines, Bioprocess Research and Development, Merck & Co., Inc., 2000 Galloping Hill Rd, Kenilworth, New Jersey 07033, United States
| | - Bruce Kilgore
- Biologics & Vaccines, Bioprocess Research and Development, Merck & Co., Inc., 2000 Galloping Hill Rd, Kenilworth, New Jersey 07033, United States
| | - Kudrat Goswami
- Biologics & Vaccines, Bioprocess Research and Development, Merck & Co., Inc., 2000 Galloping Hill Rd, Kenilworth, New Jersey 07033, United States
| | - William N. Napoli
- Biologics & Vaccines, Bioprocess Research and Development, Merck & Co., Inc., 2000 Galloping Hill Rd, Kenilworth, New Jersey 07033, United States
| | - Jayesh Desai
- Biologics & Vaccines, Bioprocess Research and Development, Merck & Co., Inc., 2000 Galloping Hill Rd, Kenilworth, New Jersey 07033, United States
| | - Jun H. Heo
- Biologics & Vaccines, Bioprocess Research and Development, Merck & Co., Inc., 2000 Galloping Hill Rd, Kenilworth, New Jersey 07033, United States
| | - Dominick Panzera
- Biologics & Vaccines, Bioprocess Research and Development, Merck & Co., Inc., 2000 Galloping Hill Rd, Kenilworth, New Jersey 07033, United States
| | - David Pollard
- Biologics & Vaccines, Bioprocess Research and Development, Merck & Co., Inc., 2000 Galloping Hill Rd, Kenilworth, New Jersey 07033, United States
| | - Daisy Richardson
- Biologics & Vaccines, Bioprocess Research and Development, Merck & Co., Inc., 2000 Galloping Hill Rd, Kenilworth, New Jersey 07033, United States
| | - Mark Brower
- Biologics & Vaccines, Bioprocess Research and Development, Merck & Co., Inc., 2000 Galloping Hill Rd, Kenilworth, New Jersey 07033, United States
| | - Douglas D. Richardson
- Biologics & Vaccines, Bioprocess Research and Development, Merck & Co., Inc., 2000 Galloping Hill Rd, Kenilworth, New Jersey 07033, United States
| |
Collapse
|
22
|
Kroening KK, Richardson DD, Afton S, Caruso JA. Screening hydrolysis products of sulfur mustard agents by high-performance liquid chromatography with inductively coupled plasma mass spectrometry detection. Anal Bioanal Chem 2009; 393:1949-56. [DOI: 10.1007/s00216-009-2642-y] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/20/2008] [Revised: 01/20/2009] [Accepted: 01/21/2009] [Indexed: 12/01/2022]
|
23
|
Kubachka KM, Richardson DD, Heitkemper DT, Caruso JA. Detection of chemical warfare agent degradation products in foods using liquid chromatography coupled to inductively coupled plasma mass spectrometry and electrospray ionization mass spectrometry. J Chromatogr A 2008; 1202:124-31. [DOI: 10.1016/j.chroma.2008.04.028] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/19/2008] [Revised: 04/10/2008] [Accepted: 04/16/2008] [Indexed: 10/22/2022]
|
24
|
Richardson DD, Caruso JA. Screening organophosphorus nerve agent degradation products in pesticide mixtures by GC-ICPMS. Anal Bioanal Chem 2007; 389:679-82. [PMID: 17602212 DOI: 10.1007/s00216-007-1408-7] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/09/2007] [Revised: 05/25/2007] [Accepted: 05/31/2007] [Indexed: 11/28/2022]
Abstract
Gas chromatography inductively coupled plasma mass spectrometry (GC-ICPMS) was utilized for the analysis of four organophosphorus nerve agent degradation products in the presence of mixtures of common organophosphorus pesticides. The first degradation products of sarin (isopropyl methylphosphonic acid, GB acid), cyclosarin (cyclohexyl methylphosphonic acid, GF acid), and soman (pinacolyl methylphosphonic acid) as well as their common final hydrolysis product methyl phosphonic acid were utilized throughout these experiments. Due to the non-volatile nature of these alkyl phosphonic acid degradation products, derivatization was performed to generate the volatile tert-butyl dimethylsilyl species. Degraded organophosphorus pesticide standards were obtained for acephate, chlorpyrifos, dichlorvos, ethion, and parathion ethyl. Mixtures consisting of three pesticides in the presence of a single nerve agent degradation product were prepared. GC-ICPMS allowed for the separation and detection of all four degradation products in the presence of pesticide mixtures in just over 12 minutes. This is the first study analyzing pesticides as interfering species for analysis of nerve agent degradation products by GC-ICPMS.
Collapse
Affiliation(s)
- Douglas D Richardson
- Department of Chemistry, McMicken College of Arts and Sciences, University of Cincinnati, Cincinnati, OH 45221-0172, USA
| | | |
Collapse
|
25
|
Richardson DD, Caruso JA. Derivatization of organophosphorus nerve agent degradation products for gas chromatography with ICPMS and TOF-MS detection. Anal Bioanal Chem 2007; 388:809-23. [PMID: 17356819 DOI: 10.1007/s00216-007-1164-8] [Citation(s) in RCA: 43] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/20/2006] [Revised: 01/24/2007] [Accepted: 01/30/2007] [Indexed: 11/30/2022]
Abstract
Separation and detection of seven V-type (venomous) and G-type (German) organophosphorus nerve agent degradation products by gas chromatography with inductively coupled plasma mass spectrometry (GC-ICPMS) is described. The nonvolatile alkyl phosphonic acid degradation products of interest included ethyl methylphosphonic acid (EMPA, VX acid), isopropyl methylphosphonic acid (IMPA, GB acid), ethyl hydrogen dimethylamidophosphate sodium salt (EDPA, GA acid), isobutyl hydrogen methylphosphonate (IBMPA, RVX acid), as well as pinacolyl methylphosphonic acid (PMPA), methylphosphonic acid (MPA), and cyclohexyl methylphosphonic acid (CMPA, GF acid). N-(tert-Butyldimethylsilyl)-N-methyltrifluroacetamide with 1% TBDMSCl was utilized to form the volatile TBDMS derivatives of the nerve agent degradation products for separation by GC. Exact mass confirmation of the formation of six of the TBDMS derivatives was obtained by GC-time of flight mass spectrometry (TOF-MS). The method developed here allowed for the separation and detection of all seven TBDMS derivatives as well as phosphate in less than ten minutes. Detection limits for the developed method were less than 5 pg with retention times and peak area precisions of less than 0.01 and 6%, respectively. This method was successfully applied to river water and soil matrices. To date this is the first work describing the analysis of chemical warfare agent (CWA) degradation products by GC-ICPMS.
Collapse
Affiliation(s)
- Douglas D Richardson
- Department of Chemistry, McMicken College of Arts and Sciences, University of Cincinnati, Cincinnati, OH 45221-0172, USA
| | | |
Collapse
|
26
|
Richardson DD, Goldmeier D. Answers To Cpd Test Questions. Int J STD AIDS 2007. [DOI: 10.1258/095646207780132406] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
|
27
|
DeNicola Cafferky K, Thompson RL, Richardson DD, Caruso JA. Determination, by inductively coupled plasma mass spectrometry, of changes in cellular metal content resulting from herpes simplex virus-1 (HSV-1) infection. Anal Bioanal Chem 2007; 387:2037-43. [PMID: 17211595 DOI: 10.1007/s00216-006-1050-9] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/01/2006] [Revised: 11/07/2006] [Accepted: 11/24/2006] [Indexed: 10/23/2022]
Abstract
Metals and metal-containing compounds are known to play important roles in many biological processes, including metabolic and detoxification pathways and the formation and function of proteins. Like all organisms, viruses are expected to contain different metals. These metals, either by themselves or in the form of metalloproteins, may be involved in the virus's ability to infect healthy cells and replicate within them. Identification and speciation of metals in control cells and in cells affected by a virus could be helpful in elucidating infection and replication mechanisms; these might, in turn, be vital to the development of more effective treatments. There has, however, been no extensive investigation of the metals specific viruses contain or affect. The objective of this study was to investigate changes in cellular metal content resulting from herpes simplex virus 1 (HSV-1) infection. Inductively coupled plasma mass spectrometry was used to identify differences between metal concentrations in uninfected and HSV-1-infected mammalian cells. Although it can be assumed that decreases in metal content are a result of cellular response to the virus, increases can be attributed either to cellular response or to the HSV-1 virus itself. Microwave digestion and flow injection methods suitable for small sample volumes were used, and the effects of different virus inactivation procedures were explored. This work is the first step in the identification of metals pertinent to HSV-1 infection and lays the foundation for future studies concentrating on characterization of these metal-associated or containing molecules.
Collapse
Affiliation(s)
- Katie DeNicola Cafferky
- Department of Chemistry, University of Cincinnati, Mail Location 0172, Cincinnati, OH 45221, USA
| | | | | | | |
Collapse
|
28
|
Wang B, Schneider SN, Dragin N, Girijashanker K, Dalton TP, He L, Miller ML, Stringer KF, Soleimani M, Richardson DD, Nebert DW. Enhanced cadmium-induced testicular necrosis and renal proximal tubule damage caused by gene-dose increase in a Slc39a8-transgenic mouse line. Am J Physiol Cell Physiol 2006; 292:C1523-35. [PMID: 17108009 DOI: 10.1152/ajpcell.00409.2006] [Citation(s) in RCA: 85] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
Resistance to cadmium (Cd)-induced testicular necrosis is an autosomal recessive trait defined as the Cdm locus. Using positional cloning, we previously identified the Slc39a8 (encoding an apical-surface ZIP8 transporter protein) as the gene most likely responsible for the phenotype. In situ hybridization revealed that endothelial cells of the testis vasculature express high ZIP8 levels in two sensitive inbred mouse strains and negligible amounts in two resistant strains. In the present study, we isolated a 168.7-kb bacterial artificial chromosome (BAC), carrying only the Slc39a8 gene, from a Cd-sensitive 129/SvJ BAC library and generated BAC-transgenic mice. The BTZIP8-3 line, having three copies of the 129/SvJ Slc39a8 gene inserted into the Cd-resistant C57BL/6J genome (having its normal two copies of the Slc39a8 gene), showed tissue-specific ZIP8 mRNA expression similar to wild-type mice, mainly in lung, testis, and kidney. The approximately 2.5-fold greater expression paralleled the fact that the BTZIP8-3 line has five copies, whereas wild-type mice have two copies, of the Slc39a8 gene. The ZIP8 mRNA and protein localized especially to endothelial cells of the testis vasculature in BTZIP8-3 mice. Cd treatment reversed Cd resistance (seen in nontransgenic littermates) to Cd sensitivity in BTZIP8-3 mice; reversal of the testicular necrosis phenotype confirms that Slc39a8 is unequivocally the Cdm locus. ZIP8 also localized specifically to the apical surface of proximal tubule cells in the BTZIP8-3 kidney. Cd treatment caused acute renal failure and signs of proximal tubular damage in the BTZIP8-3 but not nontransgenic littermates. BTZIP8-3 mice should be a useful model for studying Cd-induced disease in kidney.
Collapse
Affiliation(s)
- Bin Wang
- Department of Environmental Health, and the Center for Environmental Genetics (CEG), University Cincinnati Medical Center, Cincinnati, OH 45267-0056, USA
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
29
|
Richardson DD, Kannamkumarath SS, Wuilloud RG, Caruso JA. Hydride Generation Interface for Speciation Analysis Coupling Capillary Electrophoresis to Inductively Coupled Plasma Mass Spectrometry. Anal Chem 2004; 76:7137-42. [PMID: 15571371 DOI: 10.1021/ac049066t] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
A novel hydride generation (HG) interface for coupling capillary electrophoresis (CE) with inductively coupled plasma mass spectrometry (ICPMS) is presented in this work. The CE-HG-ICPMS interface was applied to the separation and quantitation of common arsenic species. Lack of a commercially available HG interface for CE-ICPMS led to a three concentric tube design allowing alleviation of back pressure commonly observed in CE-HG-ICPMS. Due to the high sensitivity and element-specific detection of ICPMS, quantitative analysis of As(III), As(V), monomethylarsonic acid, and dimethylarsinic acid was achieved. Optimization of CE separation conditions resulted in the use of 20 mmol L(-1) sodium borate with 2% osmotic flow modifier (pH 9.0) and -20 kV applied potential for baseline resolution of each arsenic species in the shortest time. Hydride generation conditions were optimized through multiple electrophoretic separation analyses with 5% HCl and 3% NaBH(4) (in 0.2% NaOH) determined to be the optimum conditions. After completion of system optimization, detection limits obtained for the arsenic species were less than 40 ng L(-1) with electromigration time precision less than 1% within a total analysis time of 9.0 min. Finally, the interface was used for speciation analysis of arsenic in river and tap water samples.
Collapse
Affiliation(s)
- Douglas D Richardson
- Department of Chemistry, University of Cincinnati, Cincinnati, Ohio 45221-0172, USA
| | | | | | | |
Collapse
|
30
|
|
31
|
|
32
|
|
33
|
|
34
|
|
35
|
|
36
|
Goldberg SN, Richardson DD, Palmer EL, Scott JA. Pleural effusion and ventilation/perfusion scan interpretation for acute pulmonary embolus. J Nucl Med 1996; 37:1310-3. [PMID: 8708762] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/01/2023] Open
Abstract
UNLABELLED This study was conducted to determine if pleural effusion size affects ventilation/perfusion (V/Q) scan interpretation algorithms for acute pulmonary embolus (PE). METHODS Retrospective analysis identified 163 consecutive patients undergoing angiography for PE with radiographic evidence for pleural effusion. V/Q scanning was performed in 94 (58%) of cases and reported using original Prospective Investigation of Pulmonary Embolism Diagnosis (PIOPED) criteria. Effusions were classified as small, large and/or bilateral. Radiographic and scintigraphic results were compared with regard to size and location of abnormalities. RESULTS Of the 163 patients, 57 (35%) had angiographically-proven PE, 77 (47%) had at least one large pleural effusion and 86 (53%) had a small effusion; 33 (43%) with large effusions and 24 (28%) with small effusions had emboli at angiography. Thirty-six of 119 patients (30%) with clear chest radiographs (a control group) had PE. Thus, large effusions were associated with a higher incidence of PE than those with small effusions or clear lungs (p < 0.05). Of those with V/Q scanning, 26 of 94 (28%) had a solitary large effusion, with 12 (46%) positive for emboli. V/Q-matched abnormalities limited to effusion size were found in 16 with a solitary large effusion and 10 with a solitary small effusion. In both groups, 50% were angiographically positive for emboli. Twenty-three (66%) of 35 with bilateral effusions had corresponding V/Q-matched defects at one (n = 11) or both (n = 12) lung bases, and 9 (39%) were positive for emboli. In total, 45% with a V/Q-matched defect of equivalent size to the effusion were angiographically positive for PE. CONCLUSION Pulmonary emboli are associated with pleural effusions of all sizes. Matched V/Q defects corresponding to radiographically-evident pleural effusions are of intermediate probability for PE. Thus, revision of the traditional lung scan interpretive criteria based upon pleural effusion size is not warranted.
Collapse
Affiliation(s)
- S N Goldberg
- Department of Radiology, Massachusetts General Hospital, Boston 02114, USA
| | | | | | | |
Collapse
|
37
|
Abstract
The surgical embryology and anatomy of the spleen are reported with emphasis given to ligaments, blood supply, and segmentation. The anatomic entities involved with splenic surgery are presented. Surgical applications are emphasized. Knowledge of splenic anatomy and technique, with efforts to save the organ if possible, is paramount for good results.
Collapse
|
38
|
Richardson DD, Gray SW, Skandalakis JE. The history of the small bowel. J Med Assoc Ga 1991; 80:439-43. [PMID: 1940697] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
|
39
|
Bandy DP, Theberge DM, Richardson DD. Obstruction of naso-endotracheal tube by inferior turbinate. Anesth Prog 1991; 38:27-8. [PMID: 1809051 PMCID: PMC2162367] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022] Open
Abstract
An unusual complication of naso-endotracheal tube obstruction by the inferior turbinate is reported. The delay of onset of signs and symptoms of endotracheal tube obstruction, and the lack of hemorrhage, made a difficult diagnosis.
Collapse
Affiliation(s)
- D P Bandy
- Oral and Maxillofacial Surgery, Walter Reed Army Medical Center, Washington, DC
| | | | | |
Collapse
|
40
|
Shultz RE, Richardson DD, Nespeca JA. Comparison of recovery times of isoflurane and enflurane as a sole anesthetic agent for outpatient oral surgery. Anesth Prog 1989; 36:13-4. [PMID: 2604051 PMCID: PMC2148647] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023] Open
Abstract
Patients' abilities to complete the Trieger modification of the Bender Motor Gestalt Test as an indicator of recovery time were compared following outpatient general anesthesia, using either enflurane or isoflurane on 100 patients who had their third molars removed. The time required for patients who received enflurane to satisfactorily complete the test averaged 32.7 minutes, compared with 34.6 minutes for patients who received isoflurane. Statistical analysis indicated that there was no significant difference in recovery time in this particular setting between enflurane and isoflurane.
Collapse
|
41
|
Shultz RE, Richardson DD, Kempf KK, Pevsner PH, George ED. Treatment of a central arteriovenous malformation of the mandible with cyanoacrylate: a 4-year follow-up. Oral Surg Oral Med Oral Pathol 1988; 65:267-71. [PMID: 3162574 DOI: 10.1016/0030-4220(88)90107-7] [Citation(s) in RCA: 24] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
Abstract
Large arteriovenous malformations of the jaws are relatively rare, potentially life-threatening lesions. When the lesion is not suspected, extraction of teeth can be fatal. The occurrence and treatment of arteriovenous vascular communications in the head and neck region have traditionally presented most perplexing problems. Traditional treatment has usually involved the obtaining of proximal and distal vascular control and surgical removal of the lesions, when feasible. This article presents a case that is of particular interest because it illustrates the successful use of cyanoacrylate as the only treatment for a large arteriovenous malformation of the left side of the mandible. A 4-year follow-up shows no evidence of the lesion and demonstrates complete regeneration of bone in the same area.
Collapse
Affiliation(s)
- R E Shultz
- Department of Oral and Maxillofacial Surgery, School of Dentistry, University of Missouri-Kansas City
| | | | | | | | | |
Collapse
|
42
|
Richardson DD. A clinical evaluation of chlorhexidine gluconate spray as compared with iodophor scrub for preoperative skin preparation. J Oral Maxillofac Surg 1984. [DOI: 10.1016/0278-2391(84)90364-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
43
|
Richardson DD. Granular cell myoblastoma. J Oral Maxillofac Surg 1984. [DOI: 10.1016/0278-2391(84)90472-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
44
|
Richardson DD. Canine eruption into grafted bone in maxillary alveolar cleft defects. J Oral Maxillofac Surg 1982. [DOI: 10.1016/0278-2391(82)90187-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
45
|
Richardson DD. Fatal gastric hemorrhage: A complication of cardiopulmonary resuscitation. J Oral Maxillofac Surg 1982. [DOI: 10.1016/0278-2391(82)90328-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
46
|
Abstract
1. A method of gastrin bio-assay is described which can be used on as little as 30 ng synthetic human gastrin I at a minimum concentration of 2.5 ng/ml.2. Pentagastrin or synthetic human gastrin I added to cat plasma can be stored on ice or at 4 degrees C, for periods up to 27 hr without apparent loss of gastrin activity.3. Between 1(1/2) and 13 min after the rapid I.V. injection of pentagastrin in the anaesthetized cat and between 1(1/2) and 15 min after the injection of synthetic human gastrin I, there is a rapid reduction of the gastrin concentration in the arterial plasma. The data relating log(10) gastrin concentration in arterial plasma with time can be fitted by a single term.4. Studies in vitro show that over the periods of time involved in the in vivo studies, both pentagastrin and synthetic human gastrin I are stable in cat plasma at 37 degrees C in concentrations which occurred in the circulating plasma.5. The half-life of pentagastrin in the circulating arterial plasma of the anaesthetized cat is 1.50 min (S.E. +/- 0.08) and the half-life of synthetic human gastrin I is 2.65 min (S.E. +/- 0.09).
Collapse
|
47
|
Abstract
1. A method is described for the bio-assay of gastrin activity in the anaesthetized cat, based on the acid stimulating activity of gastrin.2. A ;gastrin' of unknown potency can be assayed in terms of a stable Standard Gastrin Extract or of Synthetic Human Gastrin I.3. The sensitivity of the method is such that it will detect quantities of Synthetic Human Gastrin I at least as small as those at present described as detectable by radioimmunological techniques.4. The precision of the assay is such that it falls in the category that has been described as very precise and well suited to clinical studies.
Collapse
|